BR112012023485B1 - Marcadores moleculares para infecções do trato urinário - Google Patents
Marcadores moleculares para infecções do trato urinário Download PDFInfo
- Publication number
- BR112012023485B1 BR112012023485B1 BR112012023485-4A BR112012023485A BR112012023485B1 BR 112012023485 B1 BR112012023485 B1 BR 112012023485B1 BR 112012023485 A BR112012023485 A BR 112012023485A BR 112012023485 B1 BR112012023485 B1 BR 112012023485B1
- Authority
- BR
- Brazil
- Prior art keywords
- procalcitonin
- concentration
- urinary tract
- urine
- fact
- Prior art date
Links
- 208000019206 urinary tract infection Diseases 0.000 title claims abstract description 55
- 108010048233 Procalcitonin Proteins 0.000 claims abstract description 110
- CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 claims abstract description 110
- 210000002700 urine Anatomy 0.000 claims abstract description 69
- 238000000034 method Methods 0.000 claims abstract description 34
- 230000002485 urinary effect Effects 0.000 claims abstract description 26
- 238000003745 diagnosis Methods 0.000 claims abstract description 13
- 238000000338 in vitro Methods 0.000 claims abstract description 11
- 238000012544 monitoring process Methods 0.000 claims description 9
- 239000003153 chemical reaction reagent Substances 0.000 claims description 7
- 238000004393 prognosis Methods 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 6
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims description 6
- HQCYVSPJIOJEGA-UHFFFAOYSA-N methoxycoumarin Chemical compound C1=CC=C2OC(=O)C(OC)=CC2=C1 HQCYVSPJIOJEGA-UHFFFAOYSA-N 0.000 claims description 6
- KZUNJOHGWZRPMI-UHFFFAOYSA-N samarium atom Chemical compound [Sm] KZUNJOHGWZRPMI-UHFFFAOYSA-N 0.000 claims description 6
- 229910052772 Samarium Inorganic materials 0.000 claims description 5
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 claims description 5
- 239000013642 negative control Substances 0.000 claims description 5
- 239000013641 positive control Substances 0.000 claims description 5
- MJKVTPMWOKAVMS-UHFFFAOYSA-N 3-hydroxy-1-benzopyran-2-one Chemical compound C1=CC=C2OC(=O)C(O)=CC2=C1 MJKVTPMWOKAVMS-UHFFFAOYSA-N 0.000 claims description 4
- 229910052693 Europium Inorganic materials 0.000 claims description 3
- -1 hydroxycoumarin aminocoumarin Chemical compound 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 239000007853 buffer solution Substances 0.000 claims description 2
- JFZSJWYXTRSAAH-UHFFFAOYSA-N COC=1C(OC2=CC=CC=C2C1)=O.NC=1C(OC2=CC=CC=C2C1)=O.OC=1C(OC2=CC=CC=C2C1)=O Chemical compound COC=1C(OC2=CC=CC=C2C1)=O.NC=1C(OC2=CC=CC=C2C1)=O.OC=1C(OC2=CC=CC=C2C1)=O JFZSJWYXTRSAAH-UHFFFAOYSA-N 0.000 claims 2
- QWZHDKGQKYEBKK-UHFFFAOYSA-N 3-aminochromen-2-one Chemical compound C1=CC=C2OC(=O)C(N)=CC2=C1 QWZHDKGQKYEBKK-UHFFFAOYSA-N 0.000 claims 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 abstract description 14
- 239000003550 marker Substances 0.000 abstract description 6
- 239000000523 sample Substances 0.000 description 22
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 14
- 101100311210 Mus musculus Stard10 gene Proteins 0.000 description 9
- 229940109239 creatinine Drugs 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000011282 treatment Methods 0.000 description 6
- 239000000872 buffer Substances 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 210000001635 urinary tract Anatomy 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 208000008930 Low Back Pain Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 206010013990 dysuria Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 239000011698 potassium fluoride Substances 0.000 description 2
- 235000003270 potassium fluoride Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000008085 renal dysfunction Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 201000003126 Anuria Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 210000003771 C cell Anatomy 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 206010027566 Micturition urgency Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 206010036018 Pollakiuria Diseases 0.000 description 1
- 241000588770 Proteus mirabilis Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 230000004094 calcium homeostasis Effects 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- GWQVMPWSEVRGPY-UHFFFAOYSA-N europium cryptate Chemical compound [Eu+3].N=1C2=CC=CC=1CN(CC=1N=C(C=CC=1)C=1N=C(C3)C=CC=1)CC(N=1)=CC(C(=O)NCCN)=CC=1C(N=1)=CC(C(=O)NCCN)=CC=1CN3CC1=CC=CC2=N1 GWQVMPWSEVRGPY-UHFFFAOYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- JPMIIZHYYWMHDT-UHFFFAOYSA-N octhilinone Chemical compound CCCCCCCCN1SC=CC1=O JPMIIZHYYWMHDT-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 208000022934 urinary frequency Diseases 0.000 description 1
- 230000036318 urination frequency Effects 0.000 description 1
- 238000005353 urine analysis Methods 0.000 description 1
- 210000003741 urothelium Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/585—Calcitonins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/348—Urinary tract infections
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Absorbent Articles And Supports Therefor (AREA)
- External Artificial Organs (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITRM2010A000121 | 2010-03-18 | ||
| IT000121A ITRM20100121A1 (it) | 2010-03-18 | 2010-03-18 | Marcatori molecolari per infezioni delle vie urinarie. |
| PCT/IB2011/051073 WO2011114287A2 (en) | 2010-03-18 | 2011-03-15 | Molecular markers for urinary tract infections |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112012023485A2 BR112012023485A2 (pt) | 2016-05-24 |
| BR112012023485B1 true BR112012023485B1 (pt) | 2020-03-17 |
Family
ID=42630320
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012023485-4A BR112012023485B1 (pt) | 2010-03-18 | 2011-03-15 | Marcadores moleculares para infecções do trato urinário |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US8748195B2 (https=) |
| EP (1) | EP2548031B1 (https=) |
| JP (1) | JP5681219B2 (https=) |
| CN (1) | CN102939542B (https=) |
| BR (1) | BR112012023485B1 (https=) |
| ES (1) | ES2484720T3 (https=) |
| IT (1) | ITRM20100121A1 (https=) |
| RU (1) | RU2611371C2 (https=) |
| WO (1) | WO2011114287A2 (https=) |
| ZA (1) | ZA201206633B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2592228C2 (ru) * | 2014-04-10 | 2016-07-20 | Владимир Игоревич Павлов | Способ (варианты) и набор для диагностики инфекции мочевыводящих путей, способ лечения и определения предрасположенности к инфекции мочевыводящих путей |
| RU2679629C1 (ru) * | 2018-07-05 | 2019-02-12 | Антонина Ни | Способ диагностики воспалительного процесса органов мочевыделительной системы у детей раннего возраста |
| RU2724186C1 (ru) * | 2020-01-23 | 2020-06-22 | Наталья Борисовна Гусева | Способ лечения детей раннего возраста с рецидивирующей инфекцией мочевой системы |
| RU2766811C1 (ru) * | 2021-06-22 | 2022-03-15 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Тихоокеанский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ применения маркеров бактериального воспаления для диагностики инфекции мочевыводящих путей у детей первых трех лет жизни |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7713705B2 (en) * | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
| BRPI0616720A2 (pt) * | 2005-09-28 | 2011-06-28 | Becton Dickinson Co | método para o diagnóstico ou prognóstico de sepse em um paciente, kit para diagnóstico ou prognóstico, ou monitoração, de sepse em um paciente, e, dispositivo para o diagnóstico ou prognóstico de sepse |
| DE102007009751A1 (de) * | 2007-02-28 | 2008-09-04 | B.R.A.H.M.S Aktiengesellschaft | Verfahren zur selektiven Bestimmung von Procalcitonin 1-116 für diagnostische Zwecke sowie Antikörper und Kits zur Durchführung eines solchen Verfahrens |
| CN103123359B (zh) * | 2007-08-03 | 2015-07-29 | B.R.A.H.M.S有限公司 | 降钙素原(pct)在患原发性非传染疾病的患者的风险分级和预后中的应用 |
| JP5722587B2 (ja) * | 2009-10-13 | 2015-05-20 | ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 急性脳卒中または一過性脳虚血発作を有する患者における細菌感染の診断のためのプロカルシトニン及び抗生物質治療のガイダンス |
| JP5798133B2 (ja) * | 2010-03-08 | 2015-10-21 | ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 不特定の愁訴を示す患者における細菌感染及び抗生物質治療の指標を診断するために用いられるプロカルシトニン |
| KR102045300B1 (ko) * | 2010-05-04 | 2019-11-18 | 에티컨, 엘엘씨 | 레이저 커팅된 리테이너를 갖는 자가-유지형 시스템 |
-
2010
- 2010-03-18 IT IT000121A patent/ITRM20100121A1/it unknown
-
2011
- 2011-03-15 EP EP11713086.4A patent/EP2548031B1/en active Active
- 2011-03-15 ES ES11713086.4T patent/ES2484720T3/es active Active
- 2011-03-15 US US13/635,521 patent/US8748195B2/en active Active
- 2011-03-15 WO PCT/IB2011/051073 patent/WO2011114287A2/en not_active Ceased
- 2011-03-15 CN CN201180014501.XA patent/CN102939542B/zh active Active
- 2011-03-15 BR BR112012023485-4A patent/BR112012023485B1/pt active IP Right Grant
- 2011-03-15 RU RU2012144233A patent/RU2611371C2/ru active
- 2011-03-15 JP JP2012557648A patent/JP5681219B2/ja active Active
-
2012
- 2012-09-04 ZA ZA2012/06633A patent/ZA201206633B/en unknown
-
2014
- 2014-05-01 US US14/267,366 patent/US20140242725A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2548031A2 (en) | 2013-01-23 |
| ES2484720T3 (es) | 2014-08-12 |
| ITRM20100121A1 (it) | 2011-09-19 |
| HK1180392A1 (en) | 2013-10-18 |
| US8748195B2 (en) | 2014-06-10 |
| EP2548031B1 (en) | 2014-05-21 |
| BR112012023485A2 (pt) | 2016-05-24 |
| JP2013522618A (ja) | 2013-06-13 |
| RU2012144233A (ru) | 2014-04-27 |
| CN102939542A (zh) | 2013-02-20 |
| WO2011114287A2 (en) | 2011-09-22 |
| RU2611371C2 (ru) | 2017-02-21 |
| CN102939542B (zh) | 2015-07-08 |
| JP5681219B2 (ja) | 2015-03-04 |
| US20140242725A1 (en) | 2014-08-28 |
| WO2011114287A3 (en) | 2011-12-15 |
| ZA201206633B (en) | 2015-04-29 |
| US20130084650A1 (en) | 2013-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sierra et al. | C-reactive protein used as an early indicator of infection in patients with systemic inflammatory response syndrome | |
| ES2944613T3 (es) | proADM y/o histonas como marcadores indicadores de un acontecimiento adverso | |
| US11041864B2 (en) | Method for prediction of prognosis of sepsis | |
| Whittemore et al. | Evaluation of the association between microalbuminuria and the urine albumin-creatinine ratio and systemic disease in dogs | |
| ES2976232T3 (es) | Métodos y dispositivos mejorados para un diagnóstico exacto de infecciones | |
| CN106537146A (zh) | 生物标志 | |
| Goldstein et al. | Derivation and validation of an optimal neutrophil gelatinase-associated lipocalin cutoff to predict stage 2/3 acute kidney injury (AKI) in critically ill children | |
| JP7502430B2 (ja) | 敗血症管理 | |
| US20140120174A1 (en) | Methods of prognosis and diagnosis of sepsis | |
| Vilarinho et al. | Helicobacter pylori colonization of the adenotonsillar tissue: fact or fiction? | |
| US20140242725A1 (en) | Molecular markers for urinary tract infections | |
| US20130149725A1 (en) | Methods and compositions for diagnosis of urosepsis and urinary tract infection | |
| CN121306560A (zh) | 恶性胸腔积液预测模型的构建方法、标志物组合及应用、设备及介质 | |
| Hausfater et al. | Procalcitonin measurement in routine emergency medicine practice: comparison between two immunoassays | |
| CN119064599A (zh) | Nlrc5在制备脓毒症诊断试剂盒中的应用 | |
| ES2373009T3 (es) | Morfina endógena o un metabolito de origen natural de la misma como marcador para septicemia. | |
| US20140273032A1 (en) | Compositions and methods for diagnosis of schizophrenia | |
| HK1180392B (en) | Molecular markers for urinary tract infections | |
| CN112114138A (zh) | 一种儿童肺炎支原体抗原的检测试剂盒及检测方法 | |
| JPH1132793A (ja) | 尿路感染症の診断キット | |
| RU2734670C1 (ru) | Способ диагностики осложнений вирусной и бактериальной этиологии у больных хроническим лимфолейкозом | |
| Heilmann | Laboratory Assessment of the Gastrointestinal Tract | |
| Saito et al. | Evaluation of the clinical feasibility of severe acute respiratory syndrome coronavirus 2 antigen qualitative testing using saliva | |
| McClerking | 35. CALCITONIN AND PROCALCITONIN | |
| WO2026008623A1 (en) | A method for the diagnosis of a urinary tract infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/03/2011, OBSERVADAS AS CONDICOES LEGAIS. |